Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals (PHIO) Income Statement


Phio Pharmaceuticals Income Statement

Last quarter (Q3 2023), Phio Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Phio Pharmaceuticals's net income was $-2.78M. See Phio Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
---$ 0.00$ 21.00K$ 138.00K
Cost of Revenue
Gross Profit
Operating Expense
$ -1.01M$ 11.46M$ 13.51M$ 8.79M$ 9.01M$ 7.50M
Operating Income
$ -4.45M$ -11.46M$ -13.51M$ -8.79M$ -8.99M$ -7.36M
Net Non Operating Interest Income Expense
$ -1.00K-$ 224.00K$ -1.00K--
Other Income Expense
$ 6.00K$ 18.00K$ -233.00K$ -1.00K$ 79.00K$ 4.00K
Pretax Income
$ -4.46M$ -11.48M$ -13.29M$ -8.79M$ -8.91M$ -7.36M
Tax Provision
-$ -2.29M$ -4.34M$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -4.46M$ -11.48M$ -13.29M$ -8.79M$ -8.91M$ -7.36M
Basic EPS
$ -15.22$ -10.10-$ -1.92$ -19.35$ -57.52
Diluted EPS
$ -15.22$ -10.10$ -12.48$ -1.92$ -19.35$ -57.52
Basic Average Shares
$ 1.73B$ 1.14M$ 1.07M$ 4.59M$ 460.35K$ 127.96K
Diluted Average Shares
$ 1.73B$ 1.14M$ 1.07M$ 4.59M$ 460.35K$ 127.96K
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ -1.01M$ 11.46M$ 13.51M$ 8.79M$ 9.01M$ 7.50M
Net Income From Continuing And Discontinued Operation
$ -11.66M$ -11.48M$ -13.29M$ -8.79M$ -8.91M$ -7.36M
Normalized Income
$ -4.21M$ -13.77M-$ -8.79M$ -8.91M$ -7.36M
Interest Expense
$ -4.46M$ -11.48M$ -13.29M$ -8.79M$ -8.99M$ -7.36M
$ -4.27M$ -11.29M$ -13.10M$ -8.72M$ -8.92M$ -7.28M
Currency in USD

Phio Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis